Alzheimer’s blood biomarker detection is advancing clinically, with plasma P-tau217/181 now in major guidelines. High-cost platforms limit primary care use. Cellgenebio’s novel flow fluorescence kit enables accessible, validated multiplex testing, achieving AUC 0.904 for P-tau181 vs. A-PET.